TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 47.5% in November

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) was the recipient of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 46,900 shares, a growth of 47.5% from the November 15th total of 31,800 shares. Currently, 1.7% of the company’s shares are sold short. Based on an average trading volume of 42,200 shares, the short-interest ratio is presently 1.1 days.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on TLSI shares. Oppenheimer initiated coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They issued an “outperform” rating and a $10.00 price target on the stock. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Canaccord Genuity Group cut their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Finally, Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective for the company. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, TriSalus Life Sciences presently has a consensus rating of “Buy” and a consensus target price of $12.08.

Institutional Investors Weigh In On TriSalus Life Sciences

Several institutional investors have recently added to or reduced their stakes in TLSI. Virtu Financial LLC acquired a new stake in TriSalus Life Sciences in the 3rd quarter valued at approximately $92,000. Geode Capital Management LLC grew its stake in shares of TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after acquiring an additional 62,542 shares in the last quarter. Vestcor Inc acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at approximately $108,000. MSD Partners L.P. bought a new stake in shares of TriSalus Life Sciences in the third quarter worth $184,000. Finally, Walleye Capital LLC acquired a new position in TriSalus Life Sciences during the third quarter worth $66,000. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock traded down $0.06 on Friday, hitting $3.91. The company had a trading volume of 19,841 shares, compared to its average volume of 39,728. The stock has a 50-day moving average of $4.19 and a 200-day moving average of $5.05. TriSalus Life Sciences has a twelve month low of $3.50 and a twelve month high of $10.42. The firm has a market capitalization of $119.23 million, a P/E ratio of -1.57 and a beta of 0.56.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.